RVMDW · Insider Trading
Revolution Medicines, Inc. Warrant
Every open-market purchase and sale reported by RVMDW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Stephen Michael Kelsey | See Remarks | Sell | −4,175 | −$651.80K |
| 2026-06-18 | Jeff Cislini | General Counsel | Sell | −2,157 | −$336.75K |
| 2026-06-18 | Mark A Goldsmith | See Remarks | Sell | −10,020 | −$1.56M |
| 2026-06-18 | Jack Anders | Chief Financial Officer | Sell | −2,722 | −$424.96K |
| 2026-06-18 | Anthony Mancini | See Remarks | Sell | −4,615 | −$720.49K |
| 2026-06-17 | Margaret A Horn | Chief Operating Officer | MIXED | −3,575 | −$12.20M |
| 2026-06-15 | Margaret A Horn | Chief Operating Officer | MIXED | — | −$1.07M |
| 2026-05-28 | Anthony Mancini | See Remarks | MIXED | — | −$375.68K |
| 2026-04-29 | Anthony Mancini | See Remarks | MIXED | — | −$308.23K |
| 2026-04-17 | Mark A Goldsmith | See Remarks | MIXED | — | −$17.46M |
| 2026-03-26 | Anthony Mancini | See Remarks | MIXED | — | −$2.32M |
| 2026-03-19 | Xiaolin Wang | See Remarks | Sell | −2,010 | −$199.96K |
| 2026-03-19 | Jeff Cislini | General Counsel | Sell | −2,958 | −$291.89K |
| 2026-03-19 | Jack Anders | Chief Financial Officer | Sell | −2,753 | −$273.87K |
| 2026-03-19 | Margaret A Horn | Chief Operating Officer | Sell | −4,583 | −$455.92K |
| 2026-03-19 | Mark A Goldsmith | See Remarks | Sell | −12,871 | −$1.28M |
| 2026-03-19 | Stephen Michael Kelsey | See Remarks | Sell | −4,302 | −$427.96K |
| 2026-03-19 | Lin Wei | Chief Medical Officer | Sell | −2,073 | −$206.22K |
| 2026-03-06 | Elizabeth M Anderson | Director | G | — | — |
| 2026-03-03 | Jack Anders | Chief Financial Officer | A | +20,200 | — |
| 2026-03-03 | Jeff Cislini | General Counsel | A | +14,500 | — |
| 2026-03-03 | Margaret A Horn | Chief Operating Officer | A | +21,100 | — |
| 2026-03-03 | Mark A Goldsmith | See Remarks | MIXED | +51,100 | −$3.52M |
| 2026-03-03 | Stephen Michael Kelsey | See Remarks | A | +21,100 | — |
| 2026-03-03 | Lin Wei | Chief Medical Officer | A | +15,100 | — |
| 2026-03-03 | Xiaolin Wang | See Remarks | A | +15,100 | — |
| 2026-02-10 | Mark A Goldsmith | See Remarks | M | +24,010 | +$12.97K |
| 2026-01-23 | Jeff Cislini | General Counsel | Sell | −908 | −$104.96K |
| 2026-01-09 | Jack Anders | Chief Financial Officer | MIXED | — | −$555.50K |
| 2026-01-09 | Margaret A Horn | Chief Operating Officer | MIXED | — | −$4.66M |
| 2025-12-18 | Jack Anders | Chief Financial Officer | Sell | −3,104 | −$239.29K |
| 2025-12-18 | Margaret A Horn | Chief Operating Officer | Sell | −4,847 | −$372.33K |
| 2025-12-18 | Stephen Michael Kelsey | See Remarks | Sell | −5,447 | −$418.42K |
| 2025-12-18 | Mark A Goldsmith | See Remarks | Sell | −15,394 | −$1.18M |
| 2025-12-18 | Jeff Cislini | General Counsel | Sell | −2,688 | −$206.48K |
| 2025-11-26 | Mark A Goldsmith | See Remarks | MIXED | −6,000 | −$4.71M |
| 2025-11-26 | Jack Anders | Chief Financial Officer | MIXED | — | −$308.83K |
| 2025-11-20 | Jeff Cislini | General Counsel | MIXED | — | −$370.69K |
| 2025-11-20 | Mark A Goldsmith | See Remarks | MIXED | — | −$1.33M |
| 2025-11-14 | Mark A Goldsmith | See Remarks | MIXED | — | −$1.22M |
| 2025-11-13 | Jack Anders | Chief Financial Officer | MIXED | — | −$470.00K |
| 2025-11-12 | Mark A Goldsmith | See Remarks | MIXED | — | −$1.77M |
| 2025-10-20 | Mark A Goldsmith | See Remarks | MIXED | — | −$1.03M |
| 2025-10-20 | Jeff Cislini | General Counsel | MIXED | — | −$221.16K |
| 2025-10-15 | Stephen Michael Kelsey | See Remarks | MIXED | — | −$1.10M |
| 2025-09-26 | Jeff Cislini | General Counsel | Sell | −1,799 | −$79.62K |
| 2025-09-18 | Jack Anders | Chief Financial Officer | Sell | −2,320 | −$106.31K |
| 2025-09-18 | Jeff Cislini | General Counsel | Sell | −1,869 | −$85.65K |
| 2025-09-18 | Margaret A Horn | Chief Operating Officer | Sell | −4,775 | −$218.81K |
| 2025-09-18 | Mark A Goldsmith | See Remarks | Sell | −13,411 | −$614.56K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Alexis Borisy | Director | 2,338,884 | $20.70M |
| Thilo Schroeder | Director | 760,869 | $6.73M |
| Mark A Goldsmith | See Remarks | 331,754 | $2.94M |
| Stephen Michael Kelsey | See Remarks | 291,876 | $2.58M |
| Margaret A Horn | Chief Operating Officer | 218,622 | $1.93M |
| Jack Anders | Chief Financial Officer | 123,269 | $1.09M |
| Xiaolin Wang | See Remarks | 116,063 | $1.03M |
| Lin Wei | Chief Medical Officer | 101,366 | $897.09K |
| Sandra Horning | Director | 96,574 | $854.68K |
| Lorence H. Kim | Director | 73,090 | $646.85K |
| Jeff Cislini | General Counsel | 56,521 | $500.21K |
| Anthony Mancini | See Remarks | 49,975 | $442.28K |
| Elizabeth M Anderson | Director | 35,205 | $311.56K |
| Flavia Borellini | Director | 25,024 | $221.46K |
| Sushil Patel | Director | 23,090 | $204.35K |
| Frank Clyburn | Director | 9,738 | $86.18K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RVMDW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.